India’s healthcare manufacturing sector is witnessing a transformation, and SEPL is positioning itself at the centre of it. Traditionally known for its diversified presence across consumer goods and industrial plastics, the company is now rapidly emerging as a major player in advanced drug delivery systems — a segment expected to benefit from the global surge in biologic medicines and injectable therapies.
SEPL operates through three business verticals: Healthcare, Consumer, and Industrial. While the Consumer and Industrial divisions continue to provide operational stability and diversified earnings, the Healthcare segment has become the company’s primary growth engine. The business focuses on precision drug delivery devices, including pen injectors used in biologics, biosimilars and chronic disease therapies.
The timing appears significant. Biologic medicines now account for nearly a third of global pharmaceutical sales, with most requiring subcutaneous injection systems. At the same time, the global biosimilars market is projected to reach around USD 144 billion by 2031. Rising cases of diabetes, obesity and cancer are also fuelling demand for easy-to-use injectable treatments.
Industry analysts believe a major catalyst could emerge from the upcoming patent expiry cycle for GLP-1 drugs, beginning with semaglutide in 2026. The expiries are expected to unlock large-scale opportunities in generic injectable therapies, including treatments involving monoclonal antibodies, fertility medicines and growth hormones.
SEPL says it currently has more than 20 active development programmes tied to high-demand biologics and biosimilars. Its patented technologies and long-term pharmaceutical partnerships are expected to support recurring revenues and improve operating efficiency over time.
Financial projections indicate strong momentum. Between FY25 and FY29, the company expects revenue to grow at a compound annual rate of 29.3%, while net profit could rise nearly 45% annually. By FY29, healthcare is forecast to become SEPL’s dominant business segment, reflecting the broader shift underway in global pharmaceutical manufacturing.
